MedTrace Logo

Possible Ameliorating Effect of N- Acetylcysteine (NAC) on Type-II Diabetes Induced Nephropathy

NCT04531163 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2020-08-28

No results posted yet for this study

Summary

The study is focused on the possible improving effect of N-acetylcysteine on nephropathy of type-2 diabetic patients.

Study design: Prospective clinical based study. The aim of this work is to study the effect of N-acetylcysteine (NAC) on proteinuria and on the serum level of lipoprotein a (LPa) in diabetes induced nephropathy in type-2 diabetic patients.

Conditions

  • Diabetic Kidney Disease
  • Diabetes Mellitus, Type 2
  • Diabetic Nephropathies

Interventions

DRUG

N Acetylcysteine

(NAC) is a drug used in the experiment and participant are treated with it by 1200mg/day dose for two months.

Sponsors & Collaborators

  • Al-Azhar University

    lead OTHER

Principal Investigators

  • Huda M. Salem, PhD · Al-Azhar University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-10-01
Primary Completion
2020-11-01
Completion
2020-12-01

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04531163 on ClinicalTrials.gov